Top Page
Incannex Healthcare Limited Sponsored ADR
(NASDAQ:IXHL)
Incannex Healthcare Limited Sponsored ADR (IXHL) vs. SPDR S&P 500 ETF (SPY)
Incannex Healthcare Limited Sponsored ADR Business Overview & Revenue Model
Incannex Healthcare Limited Sponsored ADR Financial Statement Overview
| Breakdown | TTM | Jun 2025 | Sep 2024 | Jun 2023 | Jun 2022 | Jun 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 66.62K | 86.00K | ― | 0.00 | 0.00 | 1.43M |
| Gross Profit | 66.62K | 86.00K | ― | 0.00 | -4.36K | 740.54K |
| EBITDA | -45.51M | -48.09M | -27.70M | -13.55M | -10.16M | -8.57M |
| Net Income | -42.09M | -46.88M | -27.63M | -48.81M | -10.25M | -8.54M |
Balance Sheet | ||||||
| Total Assets | 75.01M | 20.45M | 17.05M | 23.78M | 26.15M | 7.00M |
| Cash, Cash Equivalents and Short-Term Investments | 68.90M | 15.04M | 5.86M | 22.12M | 25.80M | 6.84M |
| Total Debt | 163.00K | 258.00K | 373.00K | 521.00K | 0.00 | 0.00 |
| Total Liabilities | 1.60M | 7.06M | 5.83M | 2.96M | 1.39M | 566.17K |
| Stockholders Equity | 73.41M | 13.39M | 11.22M | 20.82M | 24.76M | 6.44M |
Cash Flow | ||||||
| Free Cash Flow | -10.24M | -12.52M | -16.12M | -11.06M | -8.84M | -5.18M |
| Operating Cash Flow | -10.23M | -12.51M | -15.85M | -10.75M | -8.84M | -5.18M |
| Investing Cash Flow | 58.00K | -8.00K | -277.00K | -316.00K | 0.00 | 22.00K |
| Financing Cash Flow | 18.27M | 21.40M | 0.00 | 8.18M | 28.33M | 9.30M |
Incannex Healthcare Limited Sponsored ADR Technical Analysis
Incannex Healthcare Limited Sponsored ADR Risk Analysis
Incannex Healthcare Limited Sponsored ADR Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
59 Neutral | $929.83M | -10.53 | -25.64% | ― | ― | -1.89% | |
57 Neutral | $271.71M | -22.25 | -47.05% | ― | 2.82% | 60.26% | |
53 Neutral | $74.82M | -2.47 | -24.48% | ― | 9.21% | 58.12% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | $73.59M | -21.11 | -13.08% | ― | 12.21% | 69.91% | |
46 Neutral | $50.64M | -5.55 | -114.52% | ― | -86.05% | 24.17% |
Incannex Healthcare Limited Sponsored ADR Corporate Events
On February 24, 2026, Incannex Healthcare filed a certificate of amendment in Delaware to implement a 1-for-30 reverse stock split of its common stock, effective at 4:01 p.m. Eastern Time on February 26, 2026, with post-split trading on the Nasdaq Capital Market to commence on February 27, 2026 under the existing ticker IXHL and a new CUSIP. The board-approved split, previously authorized by shareholders in May 2025, will shrink the share count from about 358.3 million to roughly 11.9 million without changing authorized capital, and is aimed at boosting the stock’s per-share trading price to help the company regain compliance with Nasdaq’s minimum bid price requirement, while rounding up any fractional positions to whole shares for investors.
The 1-for-30 consolidation will automatically adjust outstanding equity awards, option exercise prices and plan share pools on a proportional basis, leaving the economic interest of investors unchanged aside from the higher nominal share price. Operationally, the move signals management’s focus on preserving the Nasdaq listing, a key platform for liquidity and future capital raising, with most shareholders seeing their positions adjusted electronically and only holders of physical certificates required to follow transfer-agent instructions for exchanging into post-split stock.
The most recent analyst rating on (IXHL) stock is a Hold with a $0.27 price target. To see the full list of analyst forecasts on Incannex Healthcare Limited Sponsored ADR stock, see the IXHL Stock Forecast page.
On January 29, 2026, Incannex Healthcare Inc. announced the appointment of three prominent clinicians and researchers—Drs. Murray B. Stein, Andrew Cutler and Amir Kalali—to its recently formed Clinical Advisory Board to support the development of PSX-001, its synthetic psilocybin program for generalized anxiety disorder. The expanded board will provide independent guidance on clinical trial design, endpoint selection, regulatory strategy and overall development planning, a move the company positions as critical to managing the increasing complexity of PSX-001’s next clinical and regulatory phases, enhancing scientific rigor, reducing development risk and reinforcing the strategic and shareholder value foundations of this key pipeline asset.
The most recent analyst rating on (IXHL) stock is a Hold with a $0.33 price target. To see the full list of analyst forecasts on Incannex Healthcare Limited Sponsored ADR stock, see the IXHL Stock Forecast page.
On January 22, 2026, Incannex Healthcare announced it has formed a Clinical Advisory Board to guide the ongoing development of PSX-001, its synthetic psilocybin program for generalized anxiety disorder, as it moves into its next clinical and regulatory phase. The board brings together leading experts in psychiatry, neurobiology and psychopharmacology, including C. Neill Epperson, Charles B. Nemeroff and Alan F. Schatzberg, and is expected to strengthen trial design, endpoint selection, regulatory strategy and overall execution for PSX-001, underscoring the company’s push to enhance scientific rigor, manage development risk and support long-term value creation as it advances a key asset in a therapeutic area with significant unmet need.
The most recent analyst rating on (IXHL) stock is a Hold with a $0.38 price target. To see the full list of analyst forecasts on Incannex Healthcare Limited Sponsored ADR stock, see the IXHL Stock Forecast page.
Incannex Healthcare Inc. held its 2025 Annual Meeting of Stockholders on January 15, 2026, via a virtual live audio webcast, with a quorum representing approximately 34.38% of the company’s 347.7 million eligible common shares present or represented by proxy. At the meeting, shareholders elected Dr. George Anastassov and Robert Clark as directors to serve until the 2028 Annual Meeting, and ratified the appointment of Grant Thornton Audit Pty Ltd as the company’s independent registered public accounting firm for the fiscal year ending June 30, 2026, decisions that confirm continuity in board leadership and external audit oversight for the coming period.
The most recent analyst rating on (IXHL) stock is a Hold with a $0.38 price target. To see the full list of analyst forecasts on Incannex Healthcare Limited Sponsored ADR stock, see the IXHL Stock Forecast page.
On January 15, 2026, Incannex Healthcare Inc. announced it had won the Research and Development Award in the Respiratory Disorders category of the 2025 Clinical Trials Arena Excellence Awards, recognizing its work on IHL-42X, an oral fixed-dose combination therapy in development for adults with moderate-to-severe obstructive sleep apnea. The award highlights industry-wide recognition of Incannex’s science-driven approach and late-stage development strategy for IHL-42X, which is supported by a robust Phase 2 program showing favorable safety and tolerability and aims to provide a non-invasive pharmacologic alternative for patients who cannot tolerate or adhere to device-based therapies, reinforcing the company’s broader positioning as an innovator in combination therapies for chronic, underserved diseases.
The most recent analyst rating on (IXHL) stock is a Hold with a $0.37 price target. To see the full list of analyst forecasts on Incannex Healthcare Limited Sponsored ADR stock, see the IXHL Stock Forecast page.
On January 14, 2026, Incannex Healthcare reported that 2025 was a “defining” year, marked by positive Phase 2 clinical readouts in two central nervous system programs and significant strengthening of its balance sheet. The company achieved statistically significant efficacy and patient-reported benefits for its obstructive sleep apnea candidate IHL-42X in the RePOSA Phase 2 trial and secured FDA Fast Track designation for the therapy, underscoring both the unmet need in OSA and the perceived potential of its oral combination approach. Incannex also delivered positive Phase 2 results for its psilocybin-assisted therapy PSX-001 in generalized anxiety disorder, showing clinically meaningful improvement on the primary HAM-A endpoint and supportive safety and tolerability data, and it established an Obstructive Sleep Apnea Clinical Advisory Board to guide later-stage development. Financially, the company ended 2025 with more than $70 million in cash, raised $12.5 million via private placement, eliminated all outstanding Series A warrants, and authorized a $20 million share repurchase program, giving it an operating runway well into 2027 and easing near-term financing pressure as it advances its pipeline in 2026.
The most recent analyst rating on (IXHL) stock is a Hold with a $0.38 price target. To see the full list of analyst forecasts on Incannex Healthcare Limited Sponsored ADR stock, see the IXHL Stock Forecast page.
Incannex Healthcare Inc. reported that its 2025 annual meeting of stockholders, held on December 18, 2025, could not proceed due to the absence of a quorum, which was primarily attributed to its transfer agent mistakenly classifying the auditor ratification proposal as non-routine and thereby limiting discretionary broker voting. As a result, the company adjourned the meeting to January 15, 2026, to be held virtually, and is working with its transfer agent and other parties to have the auditor ratification proposal reclassified as routine, while continuing to solicit additional proxies, with previously submitted proxies remaining valid unless revoked.
On December 3, 2025, Incannex Healthcare Inc. announced that it received Fast Track designation from the U.S. Food and Drug Administration for its IHL-42X product, aimed at treating obstructive sleep apnea. This designation, supported by successful Phase 2 trial results, allows for more frequent FDA interactions and potential expedited review processes, highlighting the significance of IHL-42X in addressing unmet medical needs in sleep apnea treatment.